Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncimmune Hits IPO Target

This article was originally published in Clinica

Executive Summary

Early cancer detection specialist Oncimmune has joined AIM, the London Stock Exchange’s international market for emerging companies, after successfully completing its initial public offering and raising £11m ($15.7m) in gross proceeds. The company’s market capitalization on admission to AIM is around £66.3m; it is trading under the symbol “ONC.L”.

You may also be interested in...



Device/Diagnostics Quarterly Deal Statistics, Q2 2016

Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.

Oncimmune Taps Former Luminex, Abbott Exec To Head Asia Sales

Early lung cancer detection company Oncimmune gears up to target Asian markets with the appointment of Maarten Brusse as chief commercial officer for the region.

Q2 Breathes A Little Life Into Medtech IPO Scene

After a lackluster first quarter, the medtech IPO scene is gradually livening up with several companies their shares successfully floated on the public markets for the first time in the second quarter. But activity levels are still a far cry from the bonanza of 2015.

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel